This morning, the American Civil Liberties Union, which will be represented in Wednesday’s hearing on Section 101 reform by Senior Legislative Counsel Kate Ruane, announced an urgent joint phone briefing for members of Congress and staff to address the contention that the “Proposed Patent Bill Would Jeopardize Health Care and Harm Medical Research.” The phone briefing, taking place today at 2:30 pm EST, will be jointly held by representatives from the ACLU, the Association for Molecular Pathology, a breast cancer survivor and patient, My Gene Counsel, and Invitae. Below, Sherry Knowles, former Senior Vice President and Chief Patent Counsel at GlaxoSmithKline, rebuts the arguments made in both the ACLU’s briefing announcement and associated letter to Congress on this topic.
Recent Posts
- Stewart Defends Hands-On Approach as Squires Confirmation Looms
- Former USPTO Solicitor Urges Squires Confirmation, Accuses Acting Director of Overreach
- Other Barks & Bites for Friday, September 12: Novartis Loses Challenge to IRA Drug Price Negotiation Program; Lutnick Wants a Share of University IP Licensing; and EUIPO Announces First Copyright Conference
- Government Taking a Cut of University Royalties Would Threaten Bayh-Dole’s ROI
- Conservatives Appeal to Lutnick’s Inventor Roots in Urging Him to Drop ‘Patent Tax’ Proposal